KemPharm (NASDAQ:KMPH) will be releasing its earnings data after the market closes on Thursday, November 8th. Analysts expect KemPharm to post earnings of ($0.74) per share for the quarter.
KemPharm (NASDAQ:KMPH) last issued its earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.96) by $0.31. On average, analysts expect KemPharm to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of NASDAQ:KMPH traded down $0.04 on Tuesday, reaching $2.57. 14,041 shares of the company’s stock were exchanged, compared to its average volume of 444,545. The stock has a market capitalization of $40.75 million, a price-to-earnings ratio of -0.87 and a beta of 0.86. KemPharm has a fifty-two week low of $2.00 and a fifty-two week high of $8.40.
In related news, major shareholder Delaware Street Capital Master purchased 2,000,000 shares of KemPharm stock in a transaction dated Friday, October 5th. The stock was acquired at an average cost of $3.00 per share, with a total value of $6,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders bought 2,012,650 shares of company stock valued at $6,032,461 over the last three months. 25.90% of the stock is owned by insiders.
Several research firms have recently commented on KMPH. Oppenheimer set a $11.00 price target on shares of KemPharm and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Zacks Investment Research upgraded shares of KemPharm from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Tuesday, September 25th. CIBC restated an “outperform” rating on shares of KemPharm in a research report on Friday, September 21st. ValuEngine lowered shares of KemPharm from a “buy” rating to a “hold” rating in a research report on Tuesday, September 4th. Finally, Canaccord Genuity restated a “buy” rating and set a $11.00 price target on shares of KemPharm in a research report on Tuesday, August 14th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $10.50.
COPYRIGHT VIOLATION WARNING: “KemPharm (KMPH) Scheduled to Post Earnings on Thursday” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/11/06/kempharm-kmph-scheduled-to-post-earnings-on-thursday.html.
KemPharm Company Profile
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.